Clinical Trial: NCT03083808
Phase II Trial of Continuation Therapy in Advanced NSCLC
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Greg Durm, MD |
| Information Provided By: | Big Ten Cancer Research Consortium |
| Last Update Posted: | 2023-08-24 |
Study Overview
Brief Summary
This is a single-arm phase II study of continuation immunotherapy with pembrolizumab following initial benefit (CR, PR, or SD ≥ 3 months) with a PD-1 or PD-L1 inhibitor.
Official Title
A Phase II Trial of Chemotherapy Plus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Previously Treated With PD-1 or PD-L1 Inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029
Conditions
Non-Small-Cell Lung Cancer
Intervention / Treatment
- Drug: Pembrolizumab
Other Study ID Numbers
- BTCRC-LUN15-029
Start Date (Actual)
2017-03-20
Primary Completion Date (Actual)
2021-12-14
Study Completion Date (Actual)
2022-03-03
Enrollment (Actual)
35
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Greg Durm, MD |
| Information Provided By: | Big Ten Cancer Research Consortium |
| Last Update Posted: | 2023-08-24 |
Study Overview
Brief Summary
This is a single-arm phase II study of continuation immunotherapy with pembrolizumab following initial benefit (CR, PR, or SD ≥ 3 months) with a PD-1 or PD-L1 inhibitor.
Official Title
A Phase II Trial of Chemotherapy Plus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Previously Treated With PD-1 or PD-L1 Inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029
Conditions
Non-Small-Cell Lung Cancer
Intervention / Treatment
- Drug: Pembrolizumab
Other Study ID Numbers
- BTCRC-LUN15-029
Start Date (Actual)
2017-03-20
Primary Completion Date (Actual)
2021-12-14
Study Completion Date (Actual)
2022-03-03
Enrollment (Actual)
35
Study Type
Interventional
Phase
Phase 2